|Bid||110.36 x 800|
|Ask||111.68 x 900|
|Day's range||110.13 - 111.73|
|52-week range||81.66 - 111.73|
|Beta (3Y monthly)||0.49|
|PE ratio (TTM)||34.04|
|Earnings date||19 Nov. 2019|
|Forward dividend & yield||2.16 (1.96%)|
|1y target est||117.39|
The European data showed an average Time in Range of 73%1, a result that exceeds the recommended Time in Range consensus guidelines of 70% that were recently published2. The SmartGuard™ Auto Mode feature in the MiniMed 670G system automates and personalizes the delivery of basal insulin 24 hours a day. “The Time in Range clinical guidelines recommend that the target of effective diabetes management is the range of 70-180 mg/dL (3.9-10mmol/L) for at least 70% of time.
Zacks.com featured highlights include: Lithia Motors, Medtronic, Target, Universal Forest Products and Allegiant Travel
Medtronic plc (MDT), the global leader in medical technology, services and solutions, today announced the Envision™ Pro Continuous Glucose Monitoring (CGM) system — a fully disposable, zero calibration professional CGM system — has obtained CE (Conformité Européenne) Mark approval. Medtronic will begin commercial release in Europe and the Middle East this fall, subject to local regulatory requirements1. This new technology will empower healthcare professionals and their patients with either type 1 and type 2 diabetes to see accurate glucose levels and trends over time to develop more optimal diabetes therapy plans.
Medtronic plc (MDT), the global leader in medical technology, today announced that it will host aRobotic-Assisted Surgery (RAS) Investor Update on Tuesday, September 24, 2019, in Hartford, Conn., from 2:00 p.m. to approximately 5:30 p.m. Eastern Daylight Time. The update will include a robotic-assisted surgical procedure performed in a lab as part of the Medtronic Minimally Invasive Therapy Group’s ongoing development and testing process of its RAS technology. In addition, the update will include remarks and responses to audience questions from a panel of surgeons and Medtronic management.
Zacks.com featured highlights include: Medtronic, Symantec, Target, Popular and Baxter International
Medtronic plc (MDT), the global leader in medical technology, today announced that the National Osteoporosis Foundation (NOF) supports the VCF Care Pathway, a new evidence-based clinical care pathway developed by a multispecialty panel of experts to ensure osteoporotic vertebral compression fracture (VCF) patients receive timely and appropriate care. The VCF Care Pathway, published in Spine Journal in 20181and developed with grant support from Medtronic*, is an algorithm that has the potential to be integrated into a hospital’s electronic medical record (EMR) system, ensuring patients who present with moderate or severe back pain as their primary or secondary complaint receive standardized treatment across all departments and healthcare providers, consisting of evidence-based care and follow-up.
This collaboration is expected to bolster BioSig's (BSGM) commitment toward offering higher quality patient care by introducing innovative technological solutions to medicine.
DUBLIN and BAGSVÆRD, Denmark, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (MDT), and Novo Nordisk A/S today announced a collaboration that will develop solutions to integrate insulin dosing data from future Novo Nordisk smart insulin pens into Continuous Glucose Monitoring (CGM) devices from Medtronic, such as the Guardian™ Connect system. People with diabetes spend an average of one hour a day on self-care, amounting to a full two years devoted exclusively to their disease over their lifetime.1,2This new, non-exclusive collaboration reflects both companies′commitment to making diabetes management easier by integrating key health technologies.
Medtronic plc (MDT) today announced that it has been recognized as one of the world's leading companies for sustainability with its inclusion in the Dow Jones Sustainability North America Index (DJSI North America) for the twelfth consecutive year. The DJSI North America includes a select group of companies based on their performance across a variety of sustainability criteria, including economic performance, environmental stewardship, social responsibility, and corporate governance. This adds to the recognition Medtronic received earlier this year through its continued inclusion in the FTSE4Good Index Series.
Medtronic (MDT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Increasing adoption of cloud platforms, phones, phablets, tablets and other smart devices as well as apps is making acceptance of IoMT easier among the masses.
In the near future, there is a probability of 3D-printed implantable organs becoming a reality, thereby increasing the number of lives saved.
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.